Systemic lupus erythematosus therapeutic strategy: From immunotherapy to gut microbiota modulation

Abstract

Systemic lupus erythematosus (SLE) is characterized by a systemic dysfunction of both the innate and adaptive immune systems, leading to an attack on healthy tissues of the body. During the development of SLE, pathogenic features, such as the formation of autoantibodies against self-nuclear antigens, cause tissue damage including necrosis and fibrosis, with increased expression levels of the type Ⅰ interferon-regulated genes. Standard treatments for lupus with immunosuppressants and glucocorticoids are not effective enough but cause side effects. As an alternative, more effective immunotherapies have been developed, including monoclonal and bispecific antibodies that target B cells, T cells, co-stimulatory molecules, cytokines or their receptors, and signaling molecules. Encouraging results have been observed in clinical trials with some of these therapies. Furthermore, a chimeric antigen receptor T cell therapy has emerged as the most effective, safe, and promising treatment option for SLE, as demonstrated by successful pilot studies. Additionally, some emerging evidence suggests that gut microbiota dysbiosis may significantly contribute to the severity of SLE, and the normalization of the gut microbiota through methods such as fecal microbiota transplantation presents new opportunities for effective treatment of SLE.

Keywords

systemic lupus erythematosus / immunotherapy / monoclonal antibodies / bispecific antibodies / chimeric antigen receptor T cell / fecal microbiota transplantation

Fundings

This work was funded by the Russian Science Foundation Grant No. 21-74-10154 to A.K.

Acknowledgments

None.

References

[1] Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management[J]. J Autoimmun, 2019, 96: 1-13. doi: 10.1016/j.jaut.2018.11.001

[2] Yaniv G, Twig G, Shor DBA, et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients[J]. Autoimmun Rev, 2015, 14(1): 75-79. doi: 10.1016/j.autrev.2014.10.003

[3] Felten R, Dervovic E, Chasset F, et al. The 2018 pipeline of targeted therapies under clinical development for systemic lupus erythematosus: a systematic review of trials[J]. Autoimmun Rev, 2018, 17(8): 781-790. doi: 10.1016/j.autrev.2018.02.011

[4] Yang B, Zhao M, Wu H, et al. A comprehensive review of biological agents for lupus: beyond single target[J]. Front Immunol, 2020, 11: 539797. doi: 10.3389/fimmu.2020.539797

[5] Hafeez U, Gan HK, Scott AM. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases[J]. Curr Opin Pharmacol, 2018, 41: 114-121. doi: 10.1016/j.coph.2018.05.010

[6] Zhao Q. Bispecific antibodies for autoimmune and inflammatory diseases: clinical progress to date[J]. BioDrugs, 2020, 34(2): 111-119. doi: 10.1007/s40259-019-00400-2

[7] Felten R, Scherlinger M, Mertz P, et al. New biologics and targeted therapies in systemic lupus: from new molecular targets to new indications. A systematic review[J]. Joint Bone Spine, 2023, 90(2): 105523. doi: 10.1016/j.jbspin.2023.105523

[8] Dubey AK, Handu SS, Dubey S, et al. Belimumab: first targeted biological treatment for systemic lupus erythematosus[J]. J Pharmacol Pharmacother, 2011, 2(4): 317-319. doi: 10.4103/0976-500X.85930

[9] Kaminskiy Y, Kuznetsova V, Kudriaeva A, et al. Neglected, yet significant role of FOXP 1 in T-cell quiescence, differentiation and exhaustion[J]. Front Immunol, 2022, 13: 971045. doi: 10.3389/fimmu.2022.971045

[10] Bergmann C, Müller F, Distler JHW, et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells[J]. Ann Rheum Dis, 2023, 82(8): 1117-1120. doi: 10.1136/ard-2023-223952

[11] Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus[J]. Nat Med, 2022, 28(10): 2124-2132. doi: 10.1038/s41591-022-02017-5

[12] Kalayci FNC, Ozen S. Possible role of dysbiosis of the gut microbiome in SLE[J]. Curr Rheumatol Rep, 2023, 25(12): 247-258. doi: 10.1007/s11926-023-01115-8

[13] Ling Z, Cheng Y, Gao J, et al. Alterations of the fecal and vaginal microbiomes in patients with systemic lupus erythematosus and their associations with immunological profiles[J]. Front Immunol, 2023, 14: 1135861. doi: 10.3389/fimmu.2023.1135861

[14] Pan Q, Guo F, Huang Y, et al. Gut microbiota dysbiosis in systemic lupus erythematosus: novel insights into mechanisms and promising therapeutic strategies[J]. Front Immunol, 2021, 12: 799788. doi: 10.3389/fimmu.2021.799788

[15] Huang C, Yi P, Zhu M, et al. Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: an EXPLORER trial[J]. J Autoimmun, 2022, 130: 102844. doi: 10.1016/j.jaut.2022.102844

[16] Xin Y, Huang C, Zheng M, et al. Fecal microbiota transplantation in the treatment of systemic lupus erythematosus: what we learnt from the explorative clinical trial[J]. J Autoimmun, 2023, 141: 103058. doi: 10.1016/j.jaut.2023.103058

[17] Barber MRW, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2021, 17(9): 515-532. doi: 10.1038/s41584-021-00668-1

[18] Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis[J]. Nat Rev Nephrol, 2015, 11(6): 329-341. doi: 10.1038/nrneph.2015.33

[19] Dima A, Jurcut C, Arnaud L. Hydroxychloroquine in systemic and autoimmune diseases: where are we now?[J]. Joint Bone Spine, 2021, 88(3): 105143. doi: 10.1016/j.jbspin.2021.105143

[20] Emamikia S, Gentline C, Chatzidionysiou K, et al. Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial[J]. Scand J Rheumatol, 2018, 47(2): 131-140. doi: 10.1080/03009742.2017.1336570

[21] Robinson R. Distinct B cell receptor functions are determined by phosphorylation[J]. PLoS Biol, 2006, 4(7): e231. doi: 10.1371/journal.pbio.0040231

[22] Tanaka Y, Kubo S, Iwata S, et al. B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus[J]. Clin Immunol, 2018, 186: 21-25. doi: 10.1016/j.clim.2017.07.010

[23] Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling[J]. Semin Immunol, 2006, 18(5): 263-275. doi: 10.1016/j.smim.2006.04.006

[24] Zollars E, Bienkowska J, Czerkowicz J, et al. BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year[J]. Lupus Sci Med, 2015, 2(1): e000063. doi: 10.1136/lupus-2014-000063

[25] Mackay F, Ambrose C. The TNF family members BAFF and APRIL: the growing complexity[J]. Cytokine Growth Factor Rev, 2003, 14(3-4): 311-324. doi: 10.1016/S1359-6101(03)00023-6

[26] Vincent FB, Morand EF, Schneider P, et al. The BAFF/APRIL system in SLE pathogenesis[J]. Nat Rev Rheumatol, 2014, 10(6): 365-373. doi: 10.1038/nrrheum.2014.33

[27] Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator[J]. Arthritis Rheum, 2003, 48(11): 3253-3265. doi: 10.1002/art.11299

[28] Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2011, 377(9767): 721-731. doi: 10.1016/S0140-6736(10)61354-2

[29] Furie R, Petri M, Zamani O, et al. A phase Ⅲ randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2011, 63(12): 3918-3930. doi: 10.1002/art.30613

[30] Dörner T, Lipsky PE. Beyond pan-B-cell-directed therapy—new avenues and insights into the pathogenesis of SLE[J]. Nat Rev Rheumatol, 2016, 12(11): 645-657. doi: 10.1038/nrrheum.2016.158

[31] Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy[J]. Haematologica, 2020, 105(6): 1494-1506. doi: 10.3324/haematol.2019.243543

[32] Clark EA, Giltiay NV. CD22: a regulator of innate and adaptive B cell responses and autoimmunity[J]. Front Immunol, 2018, 9: 2235. doi: 10.3389/fimmu.2018.02235

[33] Ereño-Orbea J, Sicard T, Cui H, et al. Molecular basis of human CD22 function and therapeutic targeting[J]. Nat Commun, 2017, 8(1): 764. doi: 10.1038/s41467-017-00836-6

[34] Macauley MS, Pfrengle F, Rademacher C, et al. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis[J]. J Clin Invest, 2013, 123(7): 3074-3083. doi: 10.1172/JCI69187

[35] Daridon C, Blassfeld D, Reiter K, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus[J]. Arthritis Res Ther, 2010, 12(6): R204. doi: 10.1186/ar3179

[36] Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment[J]. Autoimmun Highlights, 2017, 8(1): 12. doi: 10.1007/s13317-017-0100-y

[37] Shipa M, Embleton-Thirsk A, Parvaz M, et al. Effectiveness of belimumab after rituximab in systemic lupus erythematosus[J]. Ann Intern Med, 2021, 174(12): 1647-1657. doi: 10.7326/M21-2078

[38] Li X, Ding Y, Zi M, et al. CD19, from bench to bedside[J]. Immunol Lett, 2017, 183: 86-95. doi: 10.1016/j.imlet.2017.01.010

[39] Espéli M, Smith KGC, Clatworthy MR. FcγRIIB and autoimmunity[J]. Immunol Rev, 2016, 269(1): 194-211. doi: 10.1111/imr.12368

[40] Horton HM, Chu SY, Ortiz EC, et al. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus[J]. J Immunol, 2011, 186(7): 4223-4233. doi: 10.4049/jimmunol.1003412

[41] Merrill J, June J, Koumpouras F, et al. FRI0176 phase 2, double-blind, randomized, placebo-controlled study of a reversible b cell inhibitor, Xmab®5871, in systemic lupus erythematosus (SLE)[J]. Ann Rheum Dis, 2019, 78(Suppl 2): 761-762.

[42] Accapezzato D, Caccavale R, Paroli MP, et al. Advances in the pathogenesis and treatment of systemic lupus erythematosus[J]. Int J Mol Sci, 2023, 24(7): 6578. doi: 10.3390/ijms24076578

[43] Chen P, Tsokos GC. T cell abnormalities in the pathogenesis of systemic lupus erythematosus: an update[J]. Curr Rheumatol Rep, 2021, 23(2): 12. doi: 10.1007/s11926-020-00978-5

[44] Shah D, Kiran R, Wanchu A, et al. Oxidative stress in systemic lupus erythematosus: relationship to Th1 cytokine and disease activity[J]. Immunol Lett, 2010, 129(1): 7-12. doi: 10.1016/j.imlet.2010.01.005

[45] Akahoshi M, Nakashima H, Tanaka Y, et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus[J]. Arthritis Rheum, 1999, 42(8): 1644-1648. doi: 10.1002/1529-0131(199908)42:8<1644::AID-ANR12>3.0.CO;2-L

[46] Sugimoto K, Morimoto S, Kaneko H, et al. Decreased IL-4 producing CD4⁺ T cells in patients with active systemic lupus erythematosus-relation to IL-12R expression[J]. Autoimmunity, 2002, 35(6): 381-387. doi: 10.1080/0891693021000008535

[47] Paroli M, Caccavale R, Fiorillo MT, et al. The double game played by Th17 cells in infection: host defense and immunopathology[J]. Pathogens, 2022, 11(12): 1547. doi: 10.3390/pathogens11121547

[48] López P, Rodríguez-Carrio J, Caminal-Montero L, et al. A pathogenic IFNα BLyS and IL-17 axis in systemic lupus erythematosus patients[J]. Sci Rep, 2016, 6: 20651. doi: 10.1038/srep20651

[49] Zickert A, Amoudruz P, Sundström Y, et al. IL-17 and IL-23 in lupus nephritis—association to histopathology and response to treatment[J]. BMC Immunol, 2015, 16(1): 7. doi: 10.1186/s12865-015-0070-7

[50] Li M, Luo L, Wu Y, et al. Elevated apoptosis and abnormal apoptosis signaling of regulatory T cells in patients with systemic lupus erythematosus[J]. Lupus, 2022, 31(12): 1441-1455. doi: 10.1177/09612033221119455

[51] Tsai YG, Liao P, Hsiao KH, et al. Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus[J]. Front Immunol, 2023, 14: 1230264. doi: 10.3389/fimmu.2023.1230264

[52] He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial[J]. Ann Rheum Dis, 2020, 79(1): 141-149. doi: 10.1136/annrheumdis-2019-215396

[53] Miao M, Xiao X, Tian J, et al. Therapeutic potential of targeting Tfr/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study[J]. Arthritis Res Ther, 2021, 23(1): 167. doi: 10.1186/s13075-021-02535-6

[54] Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy[J]. Annu Rev Immunol, 1989, 7: 445-480. doi: 10.1146/annurev.iy.07.040189.002305

[55] McCoy KD, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses[J]. Immunol Cell Biol, 1999, 77(1): 1-10. doi: 10.1046/j.1440-1711.1999.00795.x

[56] Sharabi A, Tsokos GC. T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy[J]. Nat Rev Rheumatol, 2020, 16(2): 100-112. doi: 10.1038/s41584-019-0356-x

[57] Pimentel-Quiroz VR, Ugarte-Gil MF, Alarcón GS. Abatacept for the treatment of systemic lupus erythematosus[J]. Expert Opin Investig Drugs, 2016, 25(4): 493-499. doi: 10.1517/13543784.2016.1154943

[58] Danion F, Rosine N, Belkhir R, et al. Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease[J]. Lupus, 2016, 25(13): 1440-1447. doi: 10.1177/0961203316640911

[59] Bezalel S, Guri KM, Elbirt D, et al. Type I interferon signature in systemic lupus erythematosus[J]. Isr Med Assoc J, 2014, 16(4): 246-249. doi: 10.1111/imj.12391

[60] O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease[J]. Immunity, 2012, 36(4): 542-550. doi: 10.1016/j.immuni.2012.03.014

[61] de Veer MJ, Holko M, Frevel M, et al. Functional classification of interferon-stimulated genes identified using microarrays[J]. J Leukoc Biol, 2001, 69(6): 912-920. doi: 10.1189/jlb.69.6.912

[62] Christensen SR, Shupe J, Nickerson K, et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus[J]. Immunity, 2006, 25(3): 417-428. doi: 10.1016/j.immuni.2006.07.013

[63] Tanaka Y, Tago F, Yamakawa N, et al. A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7/8 antagonist through academia-industry-government collaboration[J]. Immunol Med, 2023, 47(1): 24-29. doi: 10.1080/25785826.2023.2264023

[64] Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus[J]. Arthritis Rheumatol, 2017, 69(2): 376-386. doi: 10.1002/art.39962

[65] Koenig KF, Groeschl I, Pesickova SS, et al. Serum cytokine profile in patients with active lupus nephritis[J]. Cytokine, 2012, 60(2): 410-416. doi: 10.1016/j.cyto.2012.07.004

[66] Mok MY, Wu HJ, Lo Y, et al. The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus[J]. J Rheumatol, 2010, 37(10): 2046-2052. doi: 10.3899/jrheum.100293

[67] Mok MY, Huang FP, Ip WK, et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus[J]. Rheumatology, 2010, 49(3): 520-527. doi: 10.1093/rheumatology/kep402

[68] Pellerin A, Otero K, Czerkowicz JM, et al. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms[J]. EMBO Mol Med, 2015, 7(4): 464-476. doi: 10.15252/emmm.201404719

[69] Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus[J]. N Engl J Med, 2022, 387(10): 894-904. doi: 10.1056/NEJMoa2118025

[70] Cho SK, Vazquez T, Werth VP. Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus[J]. Expert Opin Investig Drugs, 2023, 32(5): 345-353. doi: 10.1080/13543784.2023.2212154

[71] Karnell JL, Wu Y, Mittereder N, et al. Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus[J]. Sci Transl Med, 2021, 13(595): eabf8442. doi: 10.1126/scitranslmed.abf8442

[72] Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase Ⅱ/Ⅲ systemic lupus erythematosus evaluation of rituximab trial[J]. Arthritis Rheum, 2010, 62(1): 222-233. doi: 10.1002/art.27233

[73] Kamburova EG, Koenen HJPM, Borgman KJE, et al. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function[J]. Am J Transplant, 2013, 13(6): 1503-1511. doi: 10.1111/ajt.12220

[74] Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes[J]. Immunol Today, 1994, 15(9): 450-454. doi: 10.1016/0167-5699(94)90276-3

[75] June CH, Sadelain M. Chimeric antigen receptor therapy[J]. N Engl J Med, 2018, 379(1): 64-73. doi: 10.1056/NEJMra1706169

[76] Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer[J]. Science, 2015, 348(6230): 62-68. doi: 10.1126/science.aaa4967

[77] Ledford H. The race to supercharge cancer-fighting T cells[J]. Nature, 2023, 613(7945): 626-628. doi: 10.1038/d41586-023-00177-z

[78] Ganeeva I, Zmievskaya E, Valiullina A, et al. Recent advances in the development of bioreactors for manufacturing of adoptive cell immunotherapies[J]. Bioengineering, 2022, 9(12): 808. doi: 10.3390/bioengineering9120808

[79] Titov A, Kaminskiy Y, Ganeeva I, et al. Knowns and unknowns about CAR-T cell dysfunction[J]. Cancers, 2022, 14(4): 1078. doi: 10.3390/cancers14041078

[80] Valiullina AK, Zmievskaya EA, Ganeeva IA, et al. Evaluation of CAR-T cells' cytotoxicity against modified solid tumor cell lines[J]. Biomedicines, 2023, 11(2): 626. doi: 10.3390/biomedicines11020626

[81] Kansal R, Richardson N, Neeli I, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus[J]. Sci Transl Med, 2019, 11(482): eaav1648. doi: 10.1126/scitranslmed.aav1648

[82] Jin X, Xu Q, Pu C, et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus[J]. Cell Mol Immunol, 2021, 18(8): 1896-1903. doi: 10.1038/s41423-020-0472-1

[83] Mougiakakos D, Krönke G, Völkl S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus[J]. N Engl J Med, 2021, 385(6): 567-569. doi: 10.1056/NEJMc2107725

[84] Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals[J]. Ther Adv Drug Saf, 2011, 2(3): 113-128. doi: 10.1177/2042098611406318

[85] Kuriakose A, Chirmule N, Nair P. Immunogenicity of biotherapeutics: causes and association with posttranslational modifications[J]. J Immunol Res, 2016, 2016: 1298473. doi: 10.1155/2016/1298473

[86] Mullard A. CAR T cell therapies raise hopes—and questions—for lupus and autoimmune disease[J]. Nat Rev Drug Discov, 2023, 22(11): 859-861. doi: 10.1038/d41573-023-00166-x

[87] Chasov V, Zaripov M, Mirgayazova R, et al. Promising new tools for targeting p53 mutant cancers: humoral and cell-based immunotherapies[J]. Front Immunol, 2021, 12: 707734. doi: 10.3389/fimmu.2021.707734

[88] Chames P, Van Regenmortel M, Weiss E, et al. Therapeutic antibodies: successes, limitations and hopes for the future[J]. Br J Pharmacol, 2009, 157(2): 220-233. doi: 10.1111/j.1476-5381.2009.00190.x

[89] Almagro JC, Daniels-Wells TR, Perez-Tapia SM, et al. Progress and challenges in the design and clinical development of antibodies for cancer therapy[J]. Front Immunol, 2018, 8: 1751. doi: 10.3389/fimmu.2017.01751

[90] Neelapu SS. CAR-T efficacy: is conditioning the key?[J]. Blood, 2019, 133(17): 1799-1800. doi: 10.1182/blood-2019-03-900928

[91] Sun Y, Yuan Y, Zhang B, et al. CARs: a new approach for the treatment of autoimmune diseases[J]. Sci China Life Sci, 2023, 66(4): 711-728. doi: 10.1007/s11427-022-2212-5

[92] Xiang S, Qu Y, Qian S, et al. Association between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysis[J]. Lupus Sci Med, 2022, 9(1): e000599. doi: 10.1136/lupus-2021-000599

[93] Chen B, Jia X, Xu J, et al. An autoimmunogenic and proinflammatory profile defined by the gut microbiota of patients with untreated systemic lupus erythematosus[J]. Arthritis Rheumatol, 2021, 73(2): 232-243. doi: 10.1002/art.41511

[94] Azzouz D, Omarbekova A, Heguy A, et al. Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal[J]. Ann Rheum Dis, 2019, 78(7): 947-956. doi: 10.1136/annrheumdis-2018-214856

[95] van der Meulen TA, Harmsen HJM, Vila AV, et al. Shared gut, but distinct oral microbiota composition in primary Sjögren's syndrome and systemic lupus erythematosus[J]. J Autoimmun, 2019, 97: 77-87. doi: 10.1016/j.jaut.2018.10.009

[96] Hevia A, Milani C, López P, et al. Intestinal dysbiosis associated with systemic lupus erythematosus[J]. mBio, 2014, 5(5): e01548-14. doi: 10.1128/mBio.01548-14

[97] He J, Chan T, Hong X, et al. Microbiome and metabolome analyses reveal the disruption of lipid metabolism in systemic lupus erythematosus[J]. Front Immunol, 2020, 11: 1703. doi: 10.3389/fimmu.2020.01703

[98] Manfredo Vieira S, Hiltensperger M, Kumar V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans[J]. Science, 2018, 359(6380): 1156-1161. doi: 10.1126/science.aar7201

[99] Zhang H, Liao X, Sparks JB, et al. Dynamics of gut microbiota in autoimmune lupus[J]. Appl Environ Microbiol, 2014, 80(24): 7551-7560. doi: 10.1128/AEM.02676-14

[100] Mu Q, Tavella VJ, Kirby JL, et al. Antibiotics ameliorate lupus-like symptoms in mice[J]. Sci Rep, 2017, 7(1): 13675. doi: 10.1038/s41598-017-14223-0

[101] Kim JW, Kwok SK, Choe JY, et al. Recent advances in our understanding of the link between the intestinal microbiota and systemic lupus erythematosus[J]. Int J Mol Sci, 2019, 20(19): 4871. doi: 10.3390/ijms20194871

[102] Mu Q, Kirby J, Reilly CM, et al. Leaky gut as a danger signal for autoimmune diseases[J]. Front Immunol, 2017, 8: 598. doi: 10.3389/fimmu.2017.00598

[103] Toumi E, Mezouar S, Plauzolles A, et al. Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives[J]. Lupus Sci Med, 2023, 10(1): e000776. doi: 10.1136/lupus-2022-000776

[104] Lei Y, Liu Q, Li Q, et al. Exploring the complex relationship between microbiota and systemic lupus erythematosus[J]. Curr Rheumatol Rep, 2023, 25(6): 107-116. doi: 10.1007/s11926-023-01102-z

[105] Assimakopoulos SF, Triantos C, Thomopoulos K, et al. Gut-origin sepsis in the critically ill patient: pathophysiology and treatment[J]. Infection, 2018, 46(6): 751-760. doi: 10.1007/s15010-018-1178-5

[106] Martin-Gallausiaux C, Larraufie P, Jarry A, et al. Butyrate produced by commensal bacteria down-regulates Indolamine 2, 3-Dioxygenase 1 (IDO-1) expression via a dual mechanism in human intestinal epithelial cells[J]. Front Immunol, 2018, 9: 2838. doi: 10.3389/fimmu.2018.02838

[107] Rodríguez-Carrio J, López P, Sánchez B, et al. Intestinal dysbiosis is associated with altered short-chain fatty acids and serum-free fatty acids in systemic lupus erythematosus[J]. Front Immunol, 2017, 8: 23. doi: 10.3389/fimmu.2017.00023

[108] Wu J, Pang T, Lin Z, et al. The key player in the pathogenesis of environmental influence of systemic lupus erythematosus: Aryl hydrocarbon receptor[J]. Front Immunol, 2022, 13: 965941. doi: 10.3389/fimmu.2022.965941

[109] Blank M, Barzilai O, Shoenfeld Y. Molecular mimicry and auto-immunity[J]. Clin Rev Allergy Immunol, 2007, 32(1): 111-118. doi: 10.1007/BF02686087

[110] Greiling TM, Dehner C, Chen X, et al. Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus[J]. Sci Transl Med, 2018, 10(434): eaan2306. doi: 10.1126/scitranslmed.aan2306

[111] He Z, Kong X, Shao T, et al. Alterations of the gut microbiota associated with promoting efficacy of prednisone by bromofuranone in MRL/lpr mice[J]. Front Microbiol, 2019, 10: 978. doi: 10.3389/fmicb.2019.00978

[112] Luo XM, Edwards MR, Mu Q, et al. Gut microbiota in human systemic lupus erythematosus and a mouse model of lupus[J]. Appl Environ Microbiol, 2018, 84(4): e02288-17. doi: 10.1128/AEM.02288-17

[113] Guo M, Wang H, Xu S, et al. Alteration in gut microbiota is associated with dysregulation of cytokines and glucocorticoid therapy in systemic lupus erythematosus[J]. Gut Microbes, 2020, 11(6): 1758-1773. doi: 10.1080/19490976.2020.1768644

[114] Schäfer AL, Eichhorst A, Hentze C, et al. Low dietary fiber intake links development of obesity and lupus pathogenesis[J]. Front Immunol, 2021, 12: 696810. doi: 10.3389/fimmu.2021.696810

[115] Zhang Y, Liu Q, Yu Y, et al. Early and short-term interventions in the gut microbiota affects lupus severity, progression, and treatment in MRL/lpr mice[J]. Front Microbiol, 2020, 11: 628. doi: 10.3389/fmicb.2020.00628

[116] Mu Q, Cabana-Puig X, Mao J, et al. Pregnancy and lactation interfere with the response of autoimmunity to modulation of gut microbiota[J]. Microbiome, 2019, 7(1): 105. doi: 10.1186/s40168-019-0720-8

[117] Wang W, Fan Y, Wang X. Lactobacillus: friend or foe for systemic lupus erythematosus?[J]. Front Immunol, 2022, 13: 883747. doi: 10.3389/fimmu.2022.883747

[118] López P, de Paz B, Rodríguez-Carrio J, et al. Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients[J]. Sci Rep, 2016, 6: 24072. doi: 10.1038/srep24072

[119] Mike A, Nagaoka N, Tagami Y, et al. Prevention of B220⁺ T cell expansion and prolongation of lifespan induced by Lactobacillus casei in MRL/lpr mice[J]. Clin Exp Immunol, 2001, 117(2): 368-375. doi: 10.1046/j.1365-2249.1999.00951.x

[120] Mu Q, Zhang H, Liao X, et al. Control of lupus nephritis by changes of gut microbiota[J]. Microbiome, 2017, 5(1): 73. doi: 10.1186/s40168-017-0300-8

[121] Mardani F, Mahmoudi M, Esmaeili SA, et al. In vivo study: Th1-Th17 reduction in pristane-induced systemic lupus erythematosus mice after treatment with tolerogenic Lactobacillus probiotics[J]. J Cell Physiol, 2019, 234(1): 642-649. doi: 10.1002/jcp.26819

[122] Zeng W, Shen J, Bo T, et al. Cutting edge: probiotics and fecal microbiota transplantation in immunomodulation[J]. J Immunol Res, 2019, 2019: 1603758. https://www.hindawi.com/journals/jir/2019/1603758/

[123] Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections[J]. Am J Gastroenterol, 2013, 108(4): 478-498. doi: 10.1038/ajg.2013.4

[124] Wang M, Zhu Z, Lin X, et al. Gut microbiota mediated the therapeutic efficacies and the side effects of prednisone in the treatment of MRL/lpr mice[J]. Arthritis Res Ther, 2021, 23(1): 240. doi: 10.1186/s13075-021-02620-w

[125] Johnson BM, Gaudreau MC, Al-Gadban MM, et al. Impact of dietary deviation on disease progression and gut microbiome composition in lupus-prone SNF1 mice[J]. Clin Exp Immunol, 2015, 181(2): 323-337. doi: 10.1111/cei.12609

[126] Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial[J]. Gastroenterology, 2015, 149(1): 102-109. e6.

[127] de Groot P, Nikolic T, Pellegrini S, et al. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial[J]. Gut, 2021, 70(1): 92-105. doi: 10.1136/gutjnl-2020-322630

[128] Zamudio Tiburcio Á. Improvement in a patient with active systemic lupus erythematosous treated with transplant of intestinal microbiota[J]. Gastroenterol Med Res, 2019, 3(1): 1-4. https://crimsonpublishers.com/gmr/fulltext/GMR.000551.php

[129] Cammarota G, Ianiro G, Kelly CR, et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice[J]. Gut, 2019, 68(12): 2111-2121. doi: 10.1136/gutjnl-2019-319548